Trends of use and characterisation of anti-dementia drugs users: a large multinational-network population-based study

Abstract Background An updated time-trend analysis of anti-dementia drugs (ADDs) is lacking. The aim of this study is to assess the incident rate (IR) of ADD in individuals with dementia using real-world data. Setting Primary care data (country/database) from the UK/CPRD-GOLD (2007–20), Spain/SIDIAP...

Full description

Saved in:
Bibliographic Details
Published inAge and ageing Vol. 53; no. 5
Main Authors Reyes, Carlen, Newby, Danielle, Raventós, Berta, Verhamme, Katia, Mosseveld, Mees, Prieto-Alhambra, Daniel, Burn, Edward, Duarte-Salles, Talita
Format Journal Article
LanguageEnglish
Published England Oxford University Press 01.05.2024
Oxford Publishing Limited (England)
Subjects
Age Factors
Aged
Aged, 80 and over
Catchment areas
Cohort analysis
Comorbidity
Databases, Factual
Dementia
Dementia - drug therapy
Dementia - epidemiology
Dementia disorders
Donepezil
Drug Utilization - statistics & numerical data
Drug Utilization - trends
Female
Galantamine
Humans
Male
Memantine
Middle Aged
Netherlands - epidemiology
Nootropic Agents - therapeutic use
Population studies
Population-based studies
Practice Patterns, Physicians' - trends
Primary care
Rivastigmine
Spain - epidemiology
Statistical analysis
Time Factors
United Kingdom - epidemiology
United Kingdom
Netherlands
Spain
United Kingdom > UK
cohort studies
dementia
drug utilization studies
older people
Online AccessGet full text
ISSN0002-0729
1468-2834
1468-2834
DOI10.1093/ageing/afae106

Cover

Abstract Abstract Background An updated time-trend analysis of anti-dementia drugs (ADDs) is lacking. The aim of this study is to assess the incident rate (IR) of ADD in individuals with dementia using real-world data. Setting Primary care data (country/database) from the UK/CPRD-GOLD (2007–20), Spain/SIDIAP (2010–20) and the Netherlands/IPCI (2008–20), standardised to a common data model. Methods Cohort study. Participants: dementia patients ≥40 years old with ≥1 year of previous data. Follow-up: until the end of the study period, transfer out of the catchment area, death or incident prescription of rivastigmine, galantamine, donepezil or memantine. Other variables: age/sex, type of dementia, comorbidities. Statistics: overall and yearly age/sex IR, with 95% confidence interval, per 100,000 person-years (IR per 105 PY (95%CI)). Results We identified a total of (incident anti-dementia users/dementia patients) 41,024/110,642 in UK/CPRD-GOLD, 51,667/134,927 in Spain/SIDIAP and 2,088/17,559 in the Netherlands/IPCI. In the UK, IR (per 105 PY (95%CI)) of ADD decreased from 2007 (30,829 (28,891–32,862)) to 2010 (17,793 (17,083–18,524)), then increased up to 2019 (31,601 (30,483 to 32,749)) and decrease in 2020 (24,067 (23,021–25,148)). In Spain, IR (per 105 PY (95%CI)) of ADD decreased by 72% from 2010 (51,003 (49,199–52,855)) to 2020 (14,571 (14,109–15,043)). In the Netherlands, IR (per 105 PY (95%CI)) of ADD decreased by 77% from 2009 (21,151 (14,967–29,031)) to 2020 (4763 (4176–5409)). Subjects aged ≥65–79 years and men (in the UK and the Netherlands) initiated more frequently an ADD. Conclusions Treatment of dementia remains highly heterogeneous. Further consensus in the pharmacological management of patients living with dementia is urgently needed.
AbstractList Background An updated time-trend analysis of anti-dementia drugs (ADDs) is lacking. The aim of this study is to assess the incident rate (IR) of ADD in individuals with dementia using real-world data. Setting Primary care data (country/database) from the UK/CPRD-GOLD (2007–20), Spain/SIDIAP (2010–20) and the Netherlands/IPCI (2008–20), standardised to a common data model. Methods Cohort study. Participants: dementia patients ≥40 years old with ≥1 year of previous data. Follow-up: until the end of the study period, transfer out of the catchment area, death or incident prescription of rivastigmine, galantamine, donepezil or memantine. Other variables: age/sex, type of dementia, comorbidities. Statistics: overall and yearly age/sex IR, with 95% confidence interval, per 100,000 person-years (IR per 105 PY (95%CI)). Results We identified a total of (incident anti-dementia users/dementia patients) 41,024/110,642 in UK/CPRD-GOLD, 51,667/134,927 in Spain/SIDIAP and 2,088/17,559 in the Netherlands/IPCI. In the UK, IR (per 105 PY (95%CI)) of ADD decreased from 2007 (30,829 (28,891–32,862)) to 2010 (17,793 (17,083–18,524)), then increased up to 2019 (31,601 (30,483 to 32,749)) and decrease in 2020 (24,067 (23,021–25,148)). In Spain, IR (per 105 PY (95%CI)) of ADD decreased by 72% from 2010 (51,003 (49,199–52,855)) to 2020 (14,571 (14,109–15,043)). In the Netherlands, IR (per 105 PY (95%CI)) of ADD decreased by 77% from 2009 (21,151 (14,967–29,031)) to 2020 (4763 (4176–5409)). Subjects aged ≥65–79 years and men (in the UK and the Netherlands) initiated more frequently an ADD. Conclusions Treatment of dementia remains highly heterogeneous. Further consensus in the pharmacological management of patients living with dementia is urgently needed.
An updated time-trend analysis of anti-dementia drugs (ADDs) is lacking. The aim of this study is to assess the incident rate (IR) of ADD in individuals with dementia using real-world data.BACKGROUNDAn updated time-trend analysis of anti-dementia drugs (ADDs) is lacking. The aim of this study is to assess the incident rate (IR) of ADD in individuals with dementia using real-world data.Primary care data (country/database) from the UK/CPRD-GOLD (2007-20), Spain/SIDIAP (2010-20) and the Netherlands/IPCI (2008-20), standardised to a common data model.SETTINGPrimary care data (country/database) from the UK/CPRD-GOLD (2007-20), Spain/SIDIAP (2010-20) and the Netherlands/IPCI (2008-20), standardised to a common data model.Cohort study. Participants: dementia patients ≥40 years old with ≥1 year of previous data. Follow-up: until the end of the study period, transfer out of the catchment area, death or incident prescription of rivastigmine, galantamine, donepezil or memantine. Other variables: age/sex, type of dementia, comorbidities. Statistics: overall and yearly age/sex IR, with 95% confidence interval, per 100,000 person-years (IR per 105 PY (95%CI)).METHODSCohort study. Participants: dementia patients ≥40 years old with ≥1 year of previous data. Follow-up: until the end of the study period, transfer out of the catchment area, death or incident prescription of rivastigmine, galantamine, donepezil or memantine. Other variables: age/sex, type of dementia, comorbidities. Statistics: overall and yearly age/sex IR, with 95% confidence interval, per 100,000 person-years (IR per 105 PY (95%CI)).We identified a total of (incident anti-dementia users/dementia patients) 41,024/110,642 in UK/CPRD-GOLD, 51,667/134,927 in Spain/SIDIAP and 2,088/17,559 in the Netherlands/IPCI.In the UK, IR (per 105 PY (95%CI)) of ADD decreased from 2007 (30,829 (28,891-32,862)) to 2010 (17,793 (17,083-18,524)), then increased up to 2019 (31,601 (30,483 to 32,749)) and decrease in 2020 (24,067 (23,021-25,148)). In Spain, IR (per 105 PY (95%CI)) of ADD decreased by 72% from 2010 (51,003 (49,199-52,855)) to 2020 (14,571 (14,109-15,043)). In the Netherlands, IR (per 105 PY (95%CI)) of ADD decreased by 77% from 2009 (21,151 (14,967-29,031)) to 2020 (4763 (4176-5409)). Subjects aged ≥65-79 years and men (in the UK and the Netherlands) initiated more frequently an ADD.RESULTSWe identified a total of (incident anti-dementia users/dementia patients) 41,024/110,642 in UK/CPRD-GOLD, 51,667/134,927 in Spain/SIDIAP and 2,088/17,559 in the Netherlands/IPCI.In the UK, IR (per 105 PY (95%CI)) of ADD decreased from 2007 (30,829 (28,891-32,862)) to 2010 (17,793 (17,083-18,524)), then increased up to 2019 (31,601 (30,483 to 32,749)) and decrease in 2020 (24,067 (23,021-25,148)). In Spain, IR (per 105 PY (95%CI)) of ADD decreased by 72% from 2010 (51,003 (49,199-52,855)) to 2020 (14,571 (14,109-15,043)). In the Netherlands, IR (per 105 PY (95%CI)) of ADD decreased by 77% from 2009 (21,151 (14,967-29,031)) to 2020 (4763 (4176-5409)). Subjects aged ≥65-79 years and men (in the UK and the Netherlands) initiated more frequently an ADD.Treatment of dementia remains highly heterogeneous. Further consensus in the pharmacological management of patients living with dementia is urgently needed.CONCLUSIONSTreatment of dementia remains highly heterogeneous. Further consensus in the pharmacological management of patients living with dementia is urgently needed.
An updated time-trend analysis of anti-dementia drugs (ADDs) is lacking. The aim of this study is to assess the incident rate (IR) of ADD in individuals with dementia using real-world data. Primary care data (country/database) from the UK/CPRD-GOLD (2007-20), Spain/SIDIAP (2010-20) and the Netherlands/IPCI (2008-20), standardised to a common data model. Cohort study. Participants: dementia patients ≥40 years old with ≥1 year of previous data. Follow-up: until the end of the study period, transfer out of the catchment area, death or incident prescription of rivastigmine, galantamine, donepezil or memantine. Other variables: age/sex, type of dementia, comorbidities. Statistics: overall and yearly age/sex IR, with 95% confidence interval, per 100,000 person-years (IR per 105 PY (95%CI)). We identified a total of (incident anti-dementia users/dementia patients) 41,024/110,642 in UK/CPRD-GOLD, 51,667/134,927 in Spain/SIDIAP and 2,088/17,559 in the Netherlands/IPCI.In the UK, IR (per 105 PY (95%CI)) of ADD decreased from 2007 (30,829 (28,891-32,862)) to 2010 (17,793 (17,083-18,524)), then increased up to 2019 (31,601 (30,483 to 32,749)) and decrease in 2020 (24,067 (23,021-25,148)). In Spain, IR (per 105 PY (95%CI)) of ADD decreased by 72% from 2010 (51,003 (49,199-52,855)) to 2020 (14,571 (14,109-15,043)). In the Netherlands, IR (per 105 PY (95%CI)) of ADD decreased by 77% from 2009 (21,151 (14,967-29,031)) to 2020 (4763 (4176-5409)). Subjects aged ≥65-79 years and men (in the UK and the Netherlands) initiated more frequently an ADD. Treatment of dementia remains highly heterogeneous. Further consensus in the pharmacological management of patients living with dementia is urgently needed.
Abstract Background An updated time-trend analysis of anti-dementia drugs (ADDs) is lacking. The aim of this study is to assess the incident rate (IR) of ADD in individuals with dementia using real-world data. Setting Primary care data (country/database) from the UK/CPRD-GOLD (2007–20), Spain/SIDIAP (2010–20) and the Netherlands/IPCI (2008–20), standardised to a common data model. Methods Cohort study. Participants: dementia patients ≥40 years old with ≥1 year of previous data. Follow-up: until the end of the study period, transfer out of the catchment area, death or incident prescription of rivastigmine, galantamine, donepezil or memantine. Other variables: age/sex, type of dementia, comorbidities. Statistics: overall and yearly age/sex IR, with 95% confidence interval, per 100,000 person-years (IR per 105 PY (95%CI)). Results We identified a total of (incident anti-dementia users/dementia patients) 41,024/110,642 in UK/CPRD-GOLD, 51,667/134,927 in Spain/SIDIAP and 2,088/17,559 in the Netherlands/IPCI. In the UK, IR (per 105 PY (95%CI)) of ADD decreased from 2007 (30,829 (28,891–32,862)) to 2010 (17,793 (17,083–18,524)), then increased up to 2019 (31,601 (30,483 to 32,749)) and decrease in 2020 (24,067 (23,021–25,148)). In Spain, IR (per 105 PY (95%CI)) of ADD decreased by 72% from 2010 (51,003 (49,199–52,855)) to 2020 (14,571 (14,109–15,043)). In the Netherlands, IR (per 105 PY (95%CI)) of ADD decreased by 77% from 2009 (21,151 (14,967–29,031)) to 2020 (4763 (4176–5409)). Subjects aged ≥65–79 years and men (in the UK and the Netherlands) initiated more frequently an ADD. Conclusions Treatment of dementia remains highly heterogeneous. Further consensus in the pharmacological management of patients living with dementia is urgently needed.
Author Raventós, Berta
Prieto-Alhambra, Daniel
Newby, Danielle
Duarte-Salles, Talita
Reyes, Carlen
Verhamme, Katia
Mosseveld, Mees
Burn, Edward
Author_xml – sequence: 1
  givenname: Carlen
  orcidid: 0000-0001-8486-3265
  surname: Reyes
  fullname: Reyes, Carlen
  email: creyes@idiapjgol.org
– sequence: 2
  givenname: Danielle
  surname: Newby
  fullname: Newby, Danielle
  email: danielle.newby@ndorms.ox.ac.uk
– sequence: 3
  givenname: Berta
  surname: Raventós
  fullname: Raventós, Berta
  email: braventos@idiapjgol.info
– sequence: 4
  givenname: Katia
  surname: Verhamme
  fullname: Verhamme, Katia
  email: k.verhamme@mi-erasmusmc.nl
– sequence: 5
  givenname: Mees
  surname: Mosseveld
  fullname: Mosseveld, Mees
  email: b.mosseveld@erasmusmc.nl
– sequence: 6
  givenname: Daniel
  orcidid: 0000-0002-3950-6346
  surname: Prieto-Alhambra
  fullname: Prieto-Alhambra, Daniel
  email: daniel.prietoalhambra@ndorms.ox.ac.uk
– sequence: 7
  givenname: Edward
  surname: Burn
  fullname: Burn, Edward
  email: edward.burn@ndorms.ox.ac.uk
– sequence: 8
  givenname: Talita
  surname: Duarte-Salles
  fullname: Duarte-Salles, Talita
  email: tduarte@idiapjgol.org
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38783756$$D View this record in MEDLINE/PubMed
BookMark eNqFkUtr3TAQRkVJaW7Sbrssgm7ahRM9bMvuroS-IJBNsjZjaXSr1JZcPSj59_V9tItAyGqQdM4Mmu-MnPjgkZC3nF1w1stL2KLz20uwgJy1L8iG121XiU7WJ2TDGBMVU6I_JWcp3a9H3nDxipzKTnVSNe2GlNuI3iQaLC0JKXhD9U-IoDNGlyC74Hdv4LOrDM64VqAmlm3a8TF9okAniFukc5my83sDpspj_hPiL7qEpUz7y2qEhIamXMzDa_LSwpTwzbGek7uvX26vvlfXN99-XH2-rrTsVa561TJusTcahRpbZhlq3Yy2E7rGXlkJjRKoOg1Ki3rkqql72xphbK1ka7k8Jx8OfZcYfhdMeZhd0jhN4DGUNEjWMqnWMf2Kvn-E3ocS16-sFBcdY5J1u4bvjlQZZzTDEt0M8WH4t9AVuDgAOoaUItr_CGfDLrHhkNhwTGwV6keCdnm_sBzBTU9rHw9aKMtzI_4CIYOtDA
CitedBy_id crossref_primary_10_1093_ageing_afae124
Cites_doi 10.1159/000253845
10.1111/j.1365-2125.2009.03537.x
10.1016/j.nrl.2014.02.007
10.1056/NEJMoa2212948
10.1016/S0140-6736(17)31363-6
10.3233/JAD-132639
10.1186/s12913-022-08715-7
10.1212/WNL.0000000000200176
10.3390/cells12010131
10.1093/ije/dyac068
10.3389/fphar.2021.706762
10.1016/S2468-2667(21)00249-8
10.1111/bcp.14782
10.1177/1060028020949125
10.1001/jamanetworkopen.2019.0213
10.1007/s40266-017-0481-7
10.1111/jgs.16190
10.1007/s40266-017-0446-x
10.1016/S2468-2667(17)30031-2
10.3399/bjgp10X483562
10.1097/YIC.0b013e3283339496
10.3233/JAD-132690
10.1093/jamia/ocu023
10.1136/bmjopen-2013-004119
10.1186/s13195-023-01271-0
10.1093/ije/dyac026
10.1136/bmj.l6930
10.1002/gps.5697
10.1016/j.nrl.2014.09.006
10.1007/s10072-022-06586-8
10.1001/jama.2023.13239
ContentType Journal Article
Copyright The Author(s) 2024. Published by Oxford University Press on behalf of the British Geriatrics Society. All rights reserved. For permissions, please email: journals.permissions@oup.com. 2024
The Author(s) 2024. Published by Oxford University Press on behalf of the British Geriatrics Society. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Copyright_xml – notice: The Author(s) 2024. Published by Oxford University Press on behalf of the British Geriatrics Society. All rights reserved. For permissions, please email: journals.permissions@oup.com. 2024
– notice: The Author(s) 2024. Published by Oxford University Press on behalf of the British Geriatrics Society. All rights reserved. For permissions, please email: journals.permissions@oup.com.
DBID TOX
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QJ
7T5
7TK
7U9
H94
K9.
NAPCQ
7X8
DOI 10.1093/ageing/afae106
DatabaseName Oxford Journals Open Access Collection (WRLC)
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Applied Social Sciences Index & Abstracts (ASSIA)
Immunology Abstracts
Neurosciences Abstracts
Virology and AIDS Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Nursing & Allied Health Premium
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Nursing & Allied Health Premium
Virology and AIDS Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
Applied Social Sciences Index and Abstracts (ASSIA)
Neurosciences Abstracts
MEDLINE - Academic
DatabaseTitleList Nursing & Allied Health Premium
MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: TOX
  name: Oxford Journals Open Access Collection
  url: https://academic.oup.com/journals/
  sourceTypes: Publisher
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1468-2834
ExternalDocumentID 38783756
10_1093_ageing_afae106
10.1093/ageing/afae106
Genre Multicenter Study
Journal Article
GeographicLocations United Kingdom
Netherlands
Spain
United Kingdom--UK
GeographicLocations_xml – name: United Kingdom
– name: Netherlands
– name: Spain
– name: United Kingdom--UK
GrantInformation_xml – fundername: Real World Epidemiology
– fundername: Agency for Management of University and research
GroupedDBID ---
-E4
-~X
..I
.2P
.GJ
.I3
.ZR
04C
0R~
1TH
23M
2WC
354
4.4
482
48X
53G
5GY
5RE
5VS
5WA
5WD
6J9
70D
8GL
AABZA
AACZT
AAJKP
AAJQQ
AAMVS
AAOGV
AAPGJ
AAPNW
AAPQZ
AAPXW
AARHZ
AAUAY
AAUQX
AAVAP
AAWDT
AAWTL
ABDFA
ABEHJ
ABEJV
ABEUO
ABGNP
ABIXL
ABJNI
ABKDP
ABLJU
ABNGD
ABNHQ
ABNKS
ABPQP
ABPTD
ABQLI
ABQNK
ABQTQ
ABSMQ
ABVGC
ABWST
ABXVV
ABZBJ
ACBNA
ACFRR
ACGFO
ACGFS
ACNCT
ACPQN
ACPRK
ACUFI
ACUKT
ACUTJ
ACUTO
ACVCV
ACYHN
ACZBC
ADBBV
ADEYI
ADEZT
ADGZP
ADHKW
ADHZD
ADIPN
ADMTO
ADOCK
ADQBN
ADRTK
ADVEK
ADYVW
ADZXQ
AEGPL
AEHUL
AEJOX
AEKPW
AEKSI
AEMDU
AEMQT
AENEX
AENZO
AEPUE
AETBJ
AEWNT
AFFNX
AFFQV
AFFZL
AFIYH
AFOFC
AFSHK
AFXAL
AFYAG
AGINJ
AGKEF
AGKRT
AGMDO
AGQXC
AGSYK
AGUTN
AHMBA
AHMMS
AHXPO
AI.
AIAGR
AIJHB
AJDVS
AJEEA
AJNCP
ALMA_UNASSIGNED_HOLDINGS
ALUQC
ALXQX
APIBT
APJGH
APWMN
AQDSO
AQKUS
ASPBG
ATGXG
ATTQO
AVNTJ
AVWKF
AXUDD
AZFZN
BAWUL
BAYMD
BCRHZ
BEYMZ
BHONS
BKOMP
BMSDO
BTRTY
BVRKM
BZKNY
C1A
C45
CAG
CDBKE
COF
CS3
CZ4
DAKXR
DIK
DILTD
D~K
E3Z
EBD
EBS
EE~
EIHBH
EIHJH
EJD
EMOBN
ENERS
F5P
F9B
FAC
FAS
FECEO
FEDTE
FJW
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GICCO
GJXCC
GX1
H13
H5~
HAR
HVGLF
HW0
HZ~
H~9
IAO
IEA
IHR
INH
INR
IOF
IOX
ITC
J21
J5H
JXSIZ
KAQDR
KBUDW
KOP
KQ8
KSI
KSN
LPU
M-Z
M49
MBLQV
MHKGH
N9A
NGC
NOMLY
NOYVH
NTWIH
NU-
NVLIB
O0~
O9-
OAUYM
OAWHX
OBFPC
OCZFY
ODMLO
OHH
OJQWA
OJZSN
OK1
OPAEJ
OVD
OWPYF
O~Y
P2P
PAFKI
PB-
PEELM
PQQKQ
Q1.
Q5Y
QBD
R44
RD5
RIG
RNI
ROL
ROX
ROZ
RUSNO
RW1
RXO
RZF
RZO
SV3
TCURE
TEORI
TJX
TMA
TOX
TR2
VH1
VVN
W8F
WH7
WOQ
WOW
X7H
YAYTL
YCJ
YKOAZ
YXANX
ZGI
ZKX
ZXP
~91
AAYXX
AGORE
AHGBF
AJBYB
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QJ
7T5
7TK
7U9
H94
K9.
NAPCQ
7X8
ID FETCH-LOGICAL-c397t-97601fe9dce27b60f0ecc5bf82c4e97f3a572e78ca7c24b17549f6d2df4736f13
IEDL.DBID TOX
ISSN 0002-0729
1468-2834
IngestDate Sat Sep 27 20:19:29 EDT 2025
Wed Aug 13 04:04:08 EDT 2025
Thu Apr 03 06:56:56 EDT 2025
Thu Jul 10 08:54:34 EDT 2025
Thu Apr 24 22:59:36 EDT 2025
Wed Apr 02 07:04:06 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords cohort studies
dementia
drug utilization studies
older people
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
https://creativecommons.org/licenses/by-nc-nd/4.0
The Author(s) 2024. Published by Oxford University Press on behalf of the British Geriatrics Society. All rights reserved. For permissions, please email: journals.permissions@oup.com.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c397t-97601fe9dce27b60f0ecc5bf82c4e97f3a572e78ca7c24b17549f6d2df4736f13
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-3950-6346
0000-0001-8486-3265
OpenAccessLink https://dx.doi.org/10.1093/ageing/afae106
PMID 38783756
PQID 3128003081
PQPubID 36083
ParticipantIDs proquest_miscellaneous_3060379769
proquest_journals_3128003081
pubmed_primary_38783756
crossref_primary_10_1093_ageing_afae106
crossref_citationtrail_10_1093_ageing_afae106
oup_primary_10_1093_ageing_afae106
PublicationCentury 2000
PublicationDate 2024-05-01
2024-May-01
20240501
PublicationDateYYYYMMDD 2024-05-01
PublicationDate_xml – month: 05
  year: 2024
  text: 2024-05-01
  day: 01
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: Oxford
PublicationTitle Age and ageing
PublicationTitleAlternate Age Ageing
PublicationYear 2024
Publisher Oxford University Press
Oxford Publishing Limited (England)
Publisher_xml – name: Oxford University Press
– name: Oxford Publishing Limited (England)
References GBD 2019 Dementia Forecasting Collaborators (2024061011111353900_ref1) 2022; 7
De Hoyos-Alonso (2024061011111353900_ref7) 2015; 30
2024061011111353900_ref30
Ministry of Health Welfare and Sport (2024061011111353900_ref35) 2020
Villanueva (2024061011111353900_ref8) 2016; 31
San-Juan-Rodriguez (2024061011111353900_ref22) 2019; 2
Ministerio de sanidad consumo y bienestar social. Sanidad 2019 (2024061011111353900_ref37)
Sims (2024061011111353900_ref4) 2023; 330
Villar-Fernández (2024061011111353900_ref31) 2009; 28
2024061011111353900_ref16
Walsh (2024061011111353900_ref23) 2019; 367
National Institute for Health and Care Excellence (UK) (2024061011111353900_ref15) 2018
Miculas (2024061011111353900_ref5) 2022; 12
Dyck (2024061011111353900_ref3) 2023; 388
Olazarán (2024061011111353900_ref14) 2023; 15
Day (2024061011111353900_ref2) 2022; 98
Livingston (2024061011111353900_ref21) 2017; 390
Calvó-Perxas (2024061011111353900_ref32) 2017; 34
Mukadam (2024061011111353900_ref34) 2014; 4
Vohra (2024061011111353900_ref24) 2021; 87
Battle (2024061011111353900_ref20) 2021; 2021
François (2024061011111353900_ref6) 2017; 34
Khan (2024061011111353900_ref27) 2010; 60
Du (2024061011111353900_ref33) 2022; 37
Tan (2024061011111353900_ref19) 2014; 41
Donegan (2024061011111353900_ref10) 2017; 2
Ridder (2024061011111353900_ref28) 2022; 51
Recalde (2024061011111353900_ref25) 2022; 51
Herrett (2024061011111353900_ref26) 2010; 69
Zaidi (2024061011111353900_ref17) 2021; 55
Ippoliti (2024061011111353900_ref13) 2023; 44
Saraon (2024061011111353900_ref18) 2020; 68
Versijpt (2024061011111353900_ref39) 2014; 42
Hoffmann (2024061011111353900_ref9) 2010; 25
Jelenc (2024061011111353900_ref12) 2020; 7
Netherlands Huisartsen Genootschap (2024061011111353900_ref36) 2020
Schmachtenberg (2024061011111353900_ref38) 2022; 22
Lu (2024061011111353900_ref11) 2021; 12
Voss (2024061011111353900_ref29) 2015; 22
References_xml – volume: 28
  start-page: 373
  year: 2009
  ident: 2024061011111353900_ref31
  article-title: Variability in the prescription of cholinesterase inhibitors and memantine
  publication-title: Dement Geriatr Cogn Disord
  doi: 10.1159/000253845
– volume: 69
  start-page: 4
  year: 2010
  ident: 2024061011111353900_ref26
  article-title: Validation and validity of diagnoses in the General Practice Research Database: a systematic review
  publication-title: Br J Clin Pharmacol
  doi: 10.1111/j.1365-2125.2009.03537.x
– volume: 30
  start-page: 416
  year: 2015
  ident: 2024061011111353900_ref7
  article-title: Consumption trends for specific drugs used to treat dementia in the region of Madrid (Spain) from 2002 to 2012
  publication-title: Neurologia
  doi: 10.1016/j.nrl.2014.02.007
– volume: 388
  start-page: 9
  year: 2023
  ident: 2024061011111353900_ref3
  article-title: Lecanemab in early Alzheimer's disease
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2212948
– volume: 390
  start-page: 2673
  year: 2017
  ident: 2024061011111353900_ref21
  article-title: Dementia prevention, intervention, and care
  publication-title: Lancet
  doi: 10.1016/S0140-6736(17)31363-6
– volume-title: National Dementia Strategy 2021-2030
  year: 2020
  ident: 2024061011111353900_ref35
– volume: 42
  start-page: S19
  year: 2014
  ident: 2024061011111353900_ref39
  article-title: Effectiveness and cost-effectiveness of the pharmacological treatment of Alzheimer's disease and vascular dementia
  publication-title: J Alzheimers Dis
  doi: 10.3233/JAD-132639
– volume-title: Dementia: Assessment, Management and Support for People Living with Dementia and their Carers
  year: 2018
  ident: 2024061011111353900_ref15
– ident: 2024061011111353900_ref30
  article-title: IncidencePrevalence: estimate incidence and prevalence using the OMOP common data model
– volume: 22
  start-page: 1372
  year: 2022
  ident: 2024061011111353900_ref38
  article-title: Structures for the care of people with dementia: a European comparison
  publication-title: BMC Health Serv Res
  doi: 10.1186/s12913-022-08715-7
– volume: 98
  start-page: 619
  year: 2022
  ident: 2024061011111353900_ref2
  article-title: Aducanumab use in symptomatic Alzheimer disease evidence in focus: a report of the AAN Guidelines Subcommittee
  publication-title: Neurology
  doi: 10.1212/WNL.0000000000200176
– volume: 12
  start-page: 131
  year: 2022
  ident: 2024061011111353900_ref5
  article-title: Pharmacotherapy evolution in Alzheimer's disease: current framework and relevant directions
  publication-title: Cells
  doi: 10.3390/cells12010131
– volume: 51
  start-page: e324
  year: 2022
  ident: 2024061011111353900_ref25
  article-title: Data resource profile: the information system for research in primary care (SIDIAP)
  publication-title: Int J Epidemiol
  doi: 10.1093/ije/dyac068
– volume: 12
  year: 2021
  ident: 2024061011111353900_ref11
  article-title: Gender disparities in anti-dementia medication use among older adults: health equity considerations and management of Alzheimer's disease and related dementias
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2021.706762
– volume-title: Plan integral de Alzheimer y otras demencias (2019–2023)
  ident: 2024061011111353900_ref37
– volume: 7
  start-page: e105
  year: 2022
  ident: 2024061011111353900_ref1
  article-title: Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019
  publication-title: Lancet Public Health
  doi: 10.1016/S2468-2667(21)00249-8
– volume: 87
  start-page: 3747
  year: 2021
  ident: 2024061011111353900_ref24
  article-title: Impact of deprivation, dementia prevalence and regional demography on prescribing of antidementia drugs in England: a time trend analysis
  publication-title: Br J Clin Pharmacol
  doi: 10.1111/bcp.14782
– volume: 55
  start-page: 530
  year: 2021
  ident: 2024061011111353900_ref17
  article-title: Outcomes of medication misadventure among people with cognitive impairment or dementia: a systematic review and meta-analysis
  publication-title: Ann Pharmacother
  doi: 10.1177/1060028020949125
– volume: 2
  year: 2019
  ident: 2024061011111353900_ref22
  article-title: Association of anti-dementia therapies with time to skilled nursing facility admission and cardiovascular events among elderly adults with Alzheimer disease
  publication-title: JAMA Netw Open
  doi: 10.1001/jamanetworkopen.2019.0213
– volume: 34
  start-page: 711
  year: 2017
  ident: 2024061011111353900_ref6
  article-title: Trends in drug prescription rates for dementia: an observational population-based study in France, 2006-2014
  publication-title: Drugs Aging
  doi: 10.1007/s40266-017-0481-7
– volume-title: NHS-Richtlijnen. Dementie
  year: 2020
  ident: 2024061011111353900_ref36
– volume: 68
  start-page: 216
  year: 2020
  ident: 2024061011111353900_ref18
  article-title: Screening for adverse drug reactions in dementia patients on cholinesterase inhibitor therapy
  publication-title: J Am Geriatr Soc
  doi: 10.1111/jgs.16190
– volume: 34
  start-page: 303
  year: 2017
  ident: 2024061011111353900_ref32
  article-title: Trends in the prescription and long-term utilization of anti-dementia drugs among patients with Alzheimer's disease in Spain: a cohort study using the registry of dementias of Girona
  publication-title: Drugs Aging
  doi: 10.1007/s40266-017-0446-x
– volume: 2
  start-page: e149
  year: 2017
  ident: 2024061011111353900_ref10
  article-title: Trends in diagnosis and treatment for people with dementia in the UK from 2005 to 2015: a longitudinal retrospective cohort study
  publication-title: Lancet Public Health
  doi: 10.1016/S2468-2667(17)30031-2
– volume: 60
  start-page: e128
  year: 2010
  ident: 2024061011111353900_ref27
  article-title: Validity of diagnostic coding within the General Practice Research Database: a systematic review
  publication-title: Br J Gen Pract
  doi: 10.3399/bjgp10X483562
– volume: 25
  start-page: 29
  year: 2010
  ident: 2024061011111353900_ref9
  article-title: Eight-year prescription trends of memantine and cholinesterase inhibitors among persons 65 years and older in Germany
  publication-title: Int Clin Psychopharmacol
  doi: 10.1097/YIC.0b013e3283339496
– volume: 41
  start-page: 615
  year: 2014
  ident: 2024061011111353900_ref19
  article-title: Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis
  publication-title: J Alzheimers Dis
  doi: 10.3233/JAD-132690
– volume: 22
  start-page: 553
  year: 2015
  ident: 2024061011111353900_ref29
  article-title: Feasibility and utility of applications of the common data model to multiple, disparate observational health databases
  publication-title: J Am Med Inform Assoc
  doi: 10.1093/jamia/ocu023
– volume: 4
  year: 2014
  ident: 2024061011111353900_ref34
  article-title: Diagnostic rates and treatment of dementia before and after launch of a national dementia policy: an observational study using English national databases
  publication-title: BMJ Open
  doi: 10.1136/bmjopen-2013-004119
– volume: 15
  start-page: 130
  year: 2023
  ident: 2024061011111353900_ref14
  article-title: Prevalence of treated patients with Alzheimer's disease: current trends and COVID-19 impact
  publication-title: Alzheimers Res Ther
  doi: 10.1186/s13195-023-01271-0
– volume: 51
  start-page: e314
  year: 2022
  ident: 2024061011111353900_ref28
  article-title: Data resource profile: the Integrated Primary Care Information (IPCI) database, The Netherlands
  publication-title: Int J Epidemiol
  doi: 10.1093/ije/dyac026
– volume: 367
  start-page: l6930
  year: 2019
  ident: 2024061011111353900_ref23
  article-title: France removes state funding for dementia drugs
  publication-title: BMJ
  doi: 10.1136/bmj.l6930
– volume: 37
  year: 2022
  ident: 2024061011111353900_ref33
  article-title: Time trends in psychotropic drug prescriptions in Dutch nursing home residents with dementia between 2003 and 2018
  publication-title: Int J Geriatr Psychiatry
  doi: 10.1002/gps.5697
– volume: 31
  start-page: 613
  year: 2016
  ident: 2024061011111353900_ref8
  article-title: Dementia drug consumption in the Basque Country between 2006 and 2011
  publication-title: Neurologia
  doi: 10.1016/j.nrl.2014.09.006
– volume: 44
  start-page: 1587
  year: 2023
  ident: 2024061011111353900_ref13
  article-title: Anti-dementia drugs: a descriptive study of the prescription pattern in Italy
  publication-title: Neurol Sci
  doi: 10.1007/s10072-022-06586-8
– volume-title: Sociedad Española de Neurología
  ident: 2024061011111353900_ref16
  article-title: Guías diagnósticas y terapéuticas de la Sociedad Española de Neurología 2018. 5. Guía oficial de práctica clínica en demencias
– volume: 7
  start-page: 19
  year: 2020
  ident: 2024061011111353900_ref12
  article-title: Trends in prescription of drugs for the treatment of dementia in Slovenia in the period from 2008 to 2018
  publication-title: Revija za zdravstvene vede
– volume: 330
  start-page: 512
  year: 2023
  ident: 2024061011111353900_ref4
  article-title: Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial
  publication-title: JAMA
  doi: 10.1001/jama.2023.13239
– volume: 2021
  start-page: CD013306
  year: 2021
  ident: 2024061011111353900_ref20
  article-title: Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis
  publication-title: Cochrane Database Syst Rev
SSID ssj0001512
Score 2.440455
Snippet Abstract Background An updated time-trend analysis of anti-dementia drugs (ADDs) is lacking. The aim of this study is to assess the incident rate (IR) of ADD...
An updated time-trend analysis of anti-dementia drugs (ADDs) is lacking. The aim of this study is to assess the incident rate (IR) of ADD in individuals with...
Background An updated time-trend analysis of anti-dementia drugs (ADDs) is lacking. The aim of this study is to assess the incident rate (IR) of ADD in...
SourceID proquest
pubmed
crossref
oup
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
SubjectTerms Age Factors
Aged
Aged, 80 and over
Catchment areas
Cohort analysis
Comorbidity
Databases, Factual
Dementia
Dementia - drug therapy
Dementia - epidemiology
Dementia disorders
Donepezil
Drug Utilization - statistics & numerical data
Drug Utilization - trends
Female
Galantamine
Humans
Male
Memantine
Middle Aged
Netherlands - epidemiology
Nootropic Agents - therapeutic use
Population studies
Population-based studies
Practice Patterns, Physicians' - trends
Primary care
Rivastigmine
Spain - epidemiology
Statistical analysis
Time Factors
United Kingdom - epidemiology
Title Trends of use and characterisation of anti-dementia drugs users: a large multinational-network population-based study
URI https://www.ncbi.nlm.nih.gov/pubmed/38783756
https://www.proquest.com/docview/3128003081
https://www.proquest.com/docview/3060379769
Volume 53
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1468-2834
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001512
  issn: 0002-0729
  databaseCode: KQ8
  dateStart: 19960101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1468-2834
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001512
  issn: 0002-0729
  databaseCode: DIK
  dateStart: 19720101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 1468-2834
  dateEnd: 20241001
  omitProxy: true
  ssIdentifier: ssj0001512
  issn: 0002-0729
  databaseCode: GX1
  dateStart: 19960101
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1LS8NAEF6kB2_i20otqwielqbZ7G7iTcTig-qlhd7CPqVQ0tI0_9_ZvKQ-0PNOyDKPnS87k28QulZMCccDShRjnEQ6iIlUnBMTSS215kYYfzUwfuWP0-h5xmY1WXT-Qwk_oQOIKzjFB9JJOyzJtYcAccFzJ2-z9sz1easBup4Lu6Vn_Pr4VvrZ-qXtG7IsM8xoH-3V0BDfVbY8QDs2O0S747r4fYSKqn8VLx0ucotlZrD-pFsuNezXQFVzYspbv7nEZl28515-nd9iiRe-8RuXXYTNNSDJqk5wvGpneRGf2wwuqWeP0XT0MLl_JPXUBKIBW2xI4rtcnE2MtqFQPHABWIkpF4c6solwVDIRWhFrKXQYKYAPUeK4CY2LBOVuSE9QJ1tm9gxhbWisaei4C0xkjZEiYKFLKOMxdwAsu4g0ykx1TSnuJ1ss0qq0TdNK-Wmt_C66aeVXFZnGr5JXYJs_hXqN6dI68vKUQsItSXhgd5ftMsSML4TIzC4LkAnAOwUoKumi08rk7atoLOCbnfHz_-yghzqbdWEvAJdsVB8Q-dNLv3TMDz7Q5z0
linkProvider Oxford University Press
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Trends+of+use+and+characterisation+of+anti-dementia+drugs+users%3A+a+large+multinational-network+population-based+study&rft.jtitle=Age+and+ageing&rft.au=Reyes%2C+Carlen&rft.au=Newby%2C+Danielle&rft.au=Ravent%C3%B3s%2C+Berta&rft.au=Verhamme%2C+Katia&rft.date=2024-05-01&rft.issn=0002-0729&rft.eissn=1468-2834&rft.volume=53&rft.issue=5&rft_id=info:doi/10.1093%2Fageing%2Fafae106&rft.externalDBID=n%2Fa&rft.externalDocID=10_1093_ageing_afae106
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0002-0729&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0002-0729&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0002-0729&client=summon